Engineering and Development

Chief Medical Officer

Kolon TissueGene Successfully Concludes BIO US 2025 Amid Intensified Global Interest in Its First-in-Class Disease-Modifying Therapy for Osteoarthritis, TG-C, Ahead of Phase 3 Completion

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

Treatment of intervertebral disc degeneration and discogenic back pain

Pharmaceutical composition for preventing or treating osteoarthritis

Senior Director - Marketing

Kolon TissueGene, Inc. is a pioneering biopharmaceutical company focused on advancing regenerative medicine through innovative cell and gene therapies. They are seeking a Senior Director - Marketing to lead the U.S. commercial strategy for their flagship cell therapy product, TG-C, overseeing marketing from brand strategy to commercial launch readiness.

Sign up with Google

Sign in with Google